Comparison of the Epic CTC HRD assay vs. tumor DDR mutations in metastatic castration-resistant prostate cancer (mCRPC) patients (pts)

被引：0
|
作者：
Schonhoft, Joseph [1 ]
Jendrisak, Adam [1 ]
Lee, Jerry [1 ]
Rodriguez, Angel [1 ]
Sutton, Ramsay [1 ]
Wang, Yipeng [1 ]
Dittamore, Ryan [1 ]
Landers, Mark [1 ]
机构：
[1] Epic Sci, San Diego, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-2228
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2228
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.
    Chowdhury, Simon
    Mateo, Joaquin
    Gross, Mitchell
    Armstrong, Andrew J.
    Cruz-Correa, Marcia
    Piulats, Josep M.
    Blay, Jean-Yves
    Li, Miao
    Rivas, Delcia
    Quintero, Luis
    Castro, Henry
    Nkobena, Andong
    Raponi, Mitch
    Pelham, Robert
    Landers, Mark
    Montgomery, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Liver metastases (LM) to predict for short overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).
    Kelly, William Kevin
    Halabi, Susan
    Carducci, Michael Anthony
    George, Daniel J.
    Mahoney, John Francis
    Stadler, Walter Michael
    Morris, Michael J.
    Kantoff, Philip W.
    Monk, J. P.
    Small, Eric Jay
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)
    Autio, Karen A.
    Kyriakopoulos, Christos
    Xiao, Han
    Emamekhoo, Hamid
    Danila, Daniel Costin
    Devitt, Michael Edward
    Riedel, Elyn
    Jan, Mehrin
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] Circulating tumor cells in patients with castration-resistant metastatic prostate cancer
    Danila, D. C.
    Leversha, M. A.
    Gonzalez-Espinoza, R.
    Anand, A.
    Gu, B.
    Gignac, G. A.
    Larson, S.
    Heller, G.
    Fleisher, M.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] A prospective study of comprehensive genomic testing to identify actionable variants in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Shevrin, Daniel
    Yang, Mathew
    Sabatini, Linda
    Pfanzelter, Nicklas
    Akroush, Michael
    Alnajar, Hussein
    Helseth, Larry
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 185 - 185
  • [46] Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
    Llacer Perez, C.
    Oliva Fernandez, L.
    Canada-Higueras, E.
    Saez, M. I.
    Villatoro, R.
    Montesa Pino, A.
    Herrera Imbroda, B.
    Hernandez, D.
    Lozano Mejorada, R.
    Romero Laorden, N.
    Marquez, M.
    Grau, G.
    Pineda, A.
    Lopez, F. J.
    Peinado, P.
    Alameda, D.
    Olmos, D.
    Castro, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S641 - S642
  • [47] Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Hussain, Maha
    Carducci, Michael Anthony
    Slovin, Susan F.
    Cetnar, Jeremy Paul
    Qian, Jiang
    McKeegan, Evelyn Mary
    Litvinovich, Elizabeth
    Chyla, Brenda
    Hetman, Robert
    Desai, Bhardwaj
    Giranda, Vincent L.
    Alumkal, Joshi J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [48] Circulating tumour cells (CTC) count and prostate-specific antigen (PSA) response measures in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (Doc)
    Lozano Mejorada, R.
    Lorente, D.
    Castro, E.
    Bianchini, D.
    Nombela, P.
    Sandhu, S. K.
    Romero Laorden, N.
    Cendon, Y.
    Sharp, A.
    Almagro Casado, E.
    Pacheco, M. I.
    Rescigno, P.
    Llacer, C.
    Saez, M.
    Rivera, L.
    Vitrone, F.
    Moreno, C.
    Mateo, J.
    de Bono, J. S.
    Olmos Hidalgo, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 350 - 350
  • [49] A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
    Kim, Joseph W.
    Shaffer, David R.
    Massard, Christophe
    Powles, Thomas
    Harshman, Lauren Christine
    Braiteh, Fadi S.
    Conkling, Paul R.
    Sarkar, Indrani
    Kadel, Edward E.
    Mariathasan, Sanjeev
    O'Hear, Carol
    Schiff, Christina
    Fasso, Marcella
    Carroll, Susheela
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [50] Safety and efficacy of ketoconazole (K) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Contemporary experience and prognostic indicators
    Keizman, D.
    Huang, P.
    Carducci, M. A.
    Denmeade, S. R.
    Eisenberger, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
12345